Kymera Therapeutics (NASDAQ:KYMR) Stock Price Expected to Rise, Guggenheim Analyst Says

Kymera Therapeutics (NASDAQ:KYMR) had its price objective lifted by research analysts at Guggenheim from $45.00 to $52.00 in a research report issued to clients and investors on Friday, Benzinga reports. The firm presently has a “buy” rating on the stock. Guggenheim’s target price indicates a potential upside of 12.99% from the stock’s current price.

A number of other analysts also recently issued reports on the company. Oppenheimer lifted their target price on Kymera Therapeutics from $52.00 to $56.00 and gave the company an “outperform” rating in a research report on Friday, September 27th. Truist Financial reaffirmed a “buy” rating and set a $53.00 price target (down previously from $54.00) on shares of Kymera Therapeutics in a research report on Friday. B. Riley increased their price objective on Kymera Therapeutics from $31.00 to $36.00 and gave the company a “neutral” rating in a report on Tuesday, July 9th. Wolfe Research upgraded shares of Kymera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $65.00 target price on the stock in a report on Monday, August 26th. Finally, Wells Fargo & Company increased their price target on shares of Kymera Therapeutics from $30.00 to $38.00 and gave the company an “equal weight” rating in a research note on Monday, August 12th. Four investment analysts have rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $49.15.

Kymera Therapeutics Price Performance

NASDAQ:KYMR traded down $0.15 during trading hours on Friday, reaching $46.02. 247,846 shares of the stock were exchanged, compared to its average volume of 596,527. The stock has a market cap of $2.84 billion, a PE ratio of -19.02 and a beta of 2.21. Kymera Therapeutics has a twelve month low of $9.60 and a twelve month high of $53.27. The firm has a 50 day moving average of $47.06 and a 200 day moving average of $40.57.

Kymera Therapeutics (NASDAQ:KYMR) last announced its earnings results on Thursday, October 31st. The company reported ($0.82) EPS for the quarter, topping the consensus estimate of ($0.83) by $0.01. The business had revenue of $3.74 million during the quarter, compared to analysts’ expectations of $10.34 million. Kymera Therapeutics had a negative net margin of 178.27% and a negative return on equity of 28.88%. The firm’s revenue was down 20.9% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.90) earnings per share. Equities research analysts anticipate that Kymera Therapeutics will post -2.85 earnings per share for the current year.

Insider Transactions at Kymera Therapeutics

In other Kymera Therapeutics news, Director Jeffrey W. Albers sold 5,000 shares of the company’s stock in a transaction on Monday, August 26th. The stock was sold at an average price of $49.10, for a total value of $245,500.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. In other news, Director Pamela Esposito sold 13,500 shares of the firm’s stock in a transaction that occurred on Tuesday, September 17th. The shares were sold at an average price of $48.28, for a total transaction of $651,780.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Jeffrey W. Albers sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $49.10, for a total value of $245,500.00. The disclosure for this sale can be found here. Corporate insiders own 15.82% of the company’s stock.

Hedge Funds Weigh In On Kymera Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Values First Advisors Inc. acquired a new stake in shares of Kymera Therapeutics during the 3rd quarter worth $61,000. Mirae Asset Global Investments Co. Ltd. grew its stake in Kymera Therapeutics by 27.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,336 shares of the company’s stock worth $114,000 after buying an additional 504 shares in the last quarter. Comerica Bank increased its holdings in Kymera Therapeutics by 13.7% in the 1st quarter. Comerica Bank now owns 3,324 shares of the company’s stock valued at $134,000 after buying an additional 400 shares during the period. Public Employees Retirement Association of Colorado acquired a new position in shares of Kymera Therapeutics in the 2nd quarter valued at approximately $139,000. Finally, Quest Partners LLC lifted its holdings in shares of Kymera Therapeutics by 1,402.0% during the 2nd quarter. Quest Partners LLC now owns 5,212 shares of the company’s stock worth $156,000 after acquiring an additional 4,865 shares during the period.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.